Karyopharm Therapeutics Receives a Buy from Canaccord Genuity

By Carrie Williams

Canaccord Genuity analyst Arlinda Lee maintained a Buy rating on Karyopharm Therapeutics (NASDAQ: KPTI) today and set a price target of $22. The company’s shares opened today at $12.76.

According to TipRanks.com, Lee is a 4-star analyst with an average return of 4.2% and a 44.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Aquinox Pharmaceuticals, Zynerba Pharmaceuticals, and Nektar Therapeutics.

Karyopharm Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $21.83.

The company has a one-year high of $18 and a one-year low of $7.48. Currently, Karyopharm Therapeutics has an average volume of 376.7K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, which discovers, develops, and commercializes drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma.